Phinergy: How Long Does the Funding Bridge Really Last, and What Is the Cost of the Warrant Layer
January 2026 bought Phinergy time, not a solution. Based on the 2025 cash-use pace, year-end cash, short-term deposits, the January raise, and the Series 3 exercises already completed amount to roughly an 18 to 19 month bridge, but they sit under a tradable warrant layer worth up to 36.7% of the current share count.
Why This Part Needs a Separate Follow-up
The main article argued that 2026 is still a proof year. This follow-up isolates the part that determines how much time the company actually has to deliver that proof: the funding bridge, and the economic price of the warrant layer built on top of it.
The short answer is that the company bought roughly one proof year, not much more. Year-end 2025 left Phinergy with limited liquidity relative to the business's burn rate, January 2026 added a real boost through a roughly NIS 30 million gross raise, but the company also states explicitly that its cash-flow forecast excludes future exercises of Series 2 and Series 4, and that if additional funding does not arrive through Series 3 by April 15, 2026 it can make further expense adjustments until the required financing is completed. That is not surplus capital. It is a bridge.
What really matters here is that the bridge was not built with cash alone. It was also built by selling future upside. That is why the right lens is two-part: how much time the company bought, and how much future dilution was loaded into the capital structure in order to buy that time.
How Long the Bridge Really Lasts
At the end of 2025 the company had NIS 21.506 million of cash and cash equivalents, plus another NIS 3.227 million of short-term bank deposits. Against that, the 2025 cash-use pace is still heavy: operating cash flow was negative NIS 32.063 million, investing cash flow was negative NIS 2.171 million, total lease-related cash outflow was NIS 3.040 million, and repayment to the Israel Innovation Authority was another NIS 119 thousand. On a gross cash-use basis before equity raises and warrant exercises, that is about NIS 37.4 million a year.
The picture improved after the balance-sheet date. In January 2026 the company raised roughly NIS 30 million gross, and by the approval date of the annual statements it had already received roughly NIS 4.7 million from the exercise of 2,307,354 Series 3 warrants. Add those amounts to year-end cash and short-term deposits, and the gross bridge reaches about NIS 59.4 million. Looking only at cash and cash equivalents, without the short-term deposits, the figure is about NIS 56.2 million.
At the 2025 cash-use pace, that translates into roughly 19 months of bridge in the broader reading, or about 18 months if one focuses only on direct cash. That is not an accident. The arithmetic sits very close to management's 18 month forecast.
But this is exactly where the optimistic reading has to stop. This is a gross bridge, not a comfortable cushion. It does not deduct issuance costs, and it also does not assume a step-up in investment beyond what the company recorded in 2025. That caveat matters because the annual report says the forecast includes significant investments required for the data-center plans.
The key sentence sits there as well. If the company does not succeed in raising additional financing through Series 3 exercises by April 15, 2026, management and the board believe the company can make further expense adjustments until the required financing is completed. In other words, even by the company's own wording, the 18 month window is not built on a self-funding business. It is built on year-end liquidity, a raise that already happened, exercises that already happened, and the ability to cut spend if more capital does not arrive on time.
That distinction matters. A reader who only sees the 18 month forecast line may read it as a clean runway statement. The tighter reading is different: Phinergy bought time to get through the next proof stage, but the clock is still moving quickly.
Where the Real Price of Capital Sits
January 2026 was not just an equity raise. It was a package raise. Each unit included 100 shares, 100 Series 3 warrants, and 100 Series 4 warrants, with a minimum unit price of NIS 210. That means the company did not only sell stock. It sold stock together with two layers of future optionality.
The shelf-offer report makes clear how aggressive that structure was. It estimated the economic value of each Series 3 warrant at about NIS 0.33, and the economic value of Series 4 at about NIS 0.58 if one looks at the exercise window through February 2027, or about NIS 0.73 if one looks at the exercise window through February 2028. On those assumptions, the company itself calculated an effective share price of NIS 1.04. That is the number that matters, not the headline unit price.
The raise ultimately brought in about NIS 30 million gross, and 13,971,200 Series 3 warrants and 13,971,200 Series 4 warrants were listed for trading. Later, the company also allotted another 279,424 warrants from each series to Giza Even Underwriting. In plain terms, in order to bring in roughly NIS 30 million gross, the company did not only sell equity. It also built a broad future dilution layer.
If one divides the roughly NIS 30 million gross proceeds by the shares issued to the public, the headline price comes out at around NIS 2.15 per share. But once one deducts the economic value that the company itself assigned to the two attached warrant series, the economic share price drops to around NIS 1.09. That is the core point. The warrant layer was not a free sweetener. It was part of the price of getting the raise done.
It also matters that this layer did not start in January 2026. Back in July 2025 the company had already created 17.068 million Series 2 warrants at a NIS 2.60 strike through December 15, 2026, and management also excluded those unexercised flows from its forecast. So the question is not whether there is one nearby warrant series. The question is whether the capital structure as a whole becomes a financing tool when needed, or simply hangs over the stock as a long dilution ceiling.
The Warrant Layer as Dilution, Not Just Funding
As of April 3, 2026 the company had three tradable warrant series outstanding: 17.068 million Series 2 warrants, 11.943 million Series 3 warrants, and 14.251 million Series 4 warrants. Against 117.919 million shares outstanding, that represents potential dilution of 14.5% from Series 2, another 10.1% from Series 3, and another 12.1% from Series 4. Together, the tradable warrant layer is equal to 36.7% of the current share count.
| Series | Tradable warrants | Strike price | Final exercise date | Potential cash from current balance | Potential dilution vs current shares |
|---|---|---|---|---|---|
| Series 2 | 17.068 million | NIS 2.60 | December 15, 2026 | about NIS 44.4 million | 14.5% |
| Series 3 | 11.943 million | NIS 2.00 | April 15, 2026 | about NIS 23.9 million | 10.1% |
| Series 4 | 14.251 million | NIS 2.60 through February 15, 2027, or NIS 3.60 through February 15, 2028 | February 15, 2028 | about NIS 37.1 million or about NIS 51.3 million | 12.1% |
That table says two things at once. On one side, if the full tradable warrant layer eventually converts, Phinergy could raise a very large amount of capital, about NIS 105.3 million if Series 4 is exercised in the NIS 2.60 window, or about NIS 119.6 million if it waits for the NIS 3.60 window. On the other side, that cash does not arrive for free. It comes with tens of millions of additional shares.
That leads to an important but easy-to-miss conclusion: the warrant layer is not only future upside for investors. It is also an advance sale of part of the future upside of the current shareholder base. The more the company ends up needing warrant exercises to finance the road to commercialization, the clearer it becomes that part of the future equity was already sold forward on relatively cheap terms.
Why the Market Is Not Treating That Cash as Available Yet
As of April 3, 2026 the share price stood at NIS 1.90. Series 3 traded at NIS 0.045, while its strike is NIS 2.00 and its final exercise date is April 15, 2026. Series 2 traded at NIS 0.749, but its strike is NIS 2.60 through December 2026. Series 4 traded at NIS 1.037, and it also requires NIS 2.60 through February 2027, or NIS 3.60 through February 2028.
The implication is straightforward: as of early April, none of the three series is being priced as if exercise is already sitting on the table. Series 3 is not even in the money. What the market is giving the warrants right now is time value and optionality, not certain funding.
That lines up exactly with the company's own wording. Its cash-flow forecast does not rely on future Series 2 or Series 4 exercises, and even for Series 3 it leaves itself room to cut expenses if the balance of the series does not convert in time. So anyone who looks at the total potential cash from the warrant layer as if it is already sitting in the treasury is reading the capital structure too optimistically.
That is the key distinction in this follow-up: Series 2 through Series 4 may become a meaningful source of capital later, but right now they are mainly a market test. If the stock rises because commercialization progress becomes real, the warrant layer can turn into relatively cheap follow-on capital. If not, the same layer remains a dilution ceiling without delivering the cash the company needs.
Bottom Line
January 2026 bought Phinergy time. The direct arithmetic says that time is roughly 18 to 19 months at the 2025 cash-use pace, depending on whether one includes the short-term deposits. That is enough to get through a proof year, but not enough to say the capital structure is solved.
The price of that time is a very large tradable warrant layer. It already carries potential dilution equal to 36.7% of the current share count, and its economic value was baked into the cost of the raise on day one. So the right read on Phinergy is not only how much cash sits there today, but also on what terms the next layer of equity has already been sold.
In the near term, the market is likely to care less about the large theoretical cash number from all warrants combined, and more about two much harder questions: whether Series 3 still brings in meaningful cash by April 15, 2026, and whether data-center commercialization becomes strong enough to turn Series 2 and Series 4 from dilution into financing. Until at least one of those questions is answered positively, the funding bridge remains a bridge, and the warrant layer remains part of the economic burden of the thesis.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.